PET/MRI in cancer patients: First experiences and vision from Copenhagen

Magnetic Resonance Materials in Physics, Biology and Medicine

Volumn 26, Issue 1, 2013, Pages 37-47

  Kjær, Andreas ^a   Loft, Annika ^a   Law, Ian ^a   Berthelsen, Anne Kiil ^a   Borgwardt, Lise ^a   Löfgren, Johan ^a   Johnbeck, Camilla Bardram ^a   Hansen, Adam Espe ^a   Keller, Sune ^a   Holm, Søren ^a   Højgaard, Liselotte ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; MRI; Oncology; PET; PET MRI; Tailored therapy

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; CHILD; DENMARK; EQUIPMENT; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; CHILD; CONTRAST MEDIA; DENMARK; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84874109732     PISSN: 09685243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10334-012-0357-0     Document Type: Review

References (57)

1. Kjaer A (2006) Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol 587:277-284
2. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683-693
3. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S
4. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41(8):1369-1379
5. Townsend DW, Beyer T (2002) A combined PET/CT scanner: the path to true image fusion. Br J Radiol 75 Spec No:S24-S30
6. Delbeke D, Schoder H, Martin WH, Wahl RL (2009) Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Sem Nucl Med 39(5):308-340
7. Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32(1):2-16
8. Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261(3):700-718
9. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2):102-125
10. Delso G, Furst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M, Ziegler SI (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52(12):1914-1922
11. Kalemis A, Delattre BM, Heinzer S (2012) Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective. Magn Reson Mater Phy. doi: 10.1007/s10334-012- 0330-y
12. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G (2012) Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med 53(6):928-938
13. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52-59
14. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ (2005) O-(2-[18F]fluoroethyl)-l- tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(Pt 3):678-687
15. Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34(12):1933-1942
16. Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247(2):490-498
17. Feigl GC, Safavi-Abbasi S, Gharabaghi A, Gonzalez-Felipe V, El Shawarby A, Freund HJ, Samii M (2008) Real-time 3T fMRI data of brain tumour patients for intra-operative localization of primary motor areas. Eur J Surg Oncol 34(6):708-715
18. Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M, Herms J, Koch W, Tatsch K, Tonn J-C (2005) Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57(3):505-511
19. Yaman E, Buyukberber S, Benekli M, Oner Y, Coskun U, Akmansu M, Ozturk B, Kaya AO, Uncu D, Yildiz R (2010) Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg 112(8):662-667
20. Ganslandt O, Stadlbauer A, Fahlbusch R, Kamada K, Buslei R, Blumcke I, Moser E, Nimsky C (2005) Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 56(2 Suppl):291-298
21. Stadlbauer A, Ganslandt O, Buslei R, Hammen T, Gruber S, Moser E, Buchfelder M, Salomonowitz E, Nimsky C (2006) Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 240(3):803-810
22. Stadlbauer A, Gruber S, Nimsky C, Fahlbusch R, Hammen T, Buslei R, Tomandl B, Moser E, Ganslandt O (2006) Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 238(3):958-969
23. Stadlbauer A, Nimsky C, Buslei R, Salomonowitz E, Hammen T, Buchfelder M, Moser E, Ernst-Stecken A, Ganslandt O (2007) Diffusion tensor imaging and optimized fiber tracking in glioma patients: histopathologic evaluation of tumor-invaded white matter structures. NeuroImage 34(3):949-956
24. Gruner JM, Paamand R, Kosteljanetz M, Broholm H, Hojgaard L, Law I (2012) Brain perfusion CT compared with (15)O-H (2)O PET in patients with primary brain tumours. Eur J Nucl Med Mol Imaging 39(11):1691-1701
25. Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39(6):1021-1029
26. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G (2011) O-(2-18F-fluoroethyl)-l-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 52(6):856-864
27. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511-519
28. Thorwarth D, Muller AC, Pfannenberg C, Beyer T (2012) Combined PET/MR Imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients. Recent Result Cancer Res 194:425-439
29. Kumar R, Shandal V, Shamim SA, Halanaik D, Malhotra A (2010) Clinical applications of PET and PET/CT in pediatric malignancies. Expert Rev Anticancer Ther 10(5):755-768
30. Purz S, Mauz-Korholz C, Korholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O, Kranert WT, Weber WA, Haberkorn U, Hundsdorfer P, Ehlert K, Becker M, Rossler J, Kulozik AE, Sabri O, Kluge R (2011) [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 29(26):3523-3528
31. Kluge R, Korholz D (2011) [Role of FDG-PET in staging and therapy of children with Hodgkin lymphoma]. Die Bedeutung des FDG-PET fur die Stadieneinteilung und Therapie des Hodgkin-Lymphoms im Kindesalter. Klin Padiatr 223(6):315-319
32. Fahey FH, Treves ST, Adelstein SJ (2011) Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med 52(8):1240-1251
33. Lassmann M, Biassoni L, Monsieurs M, Franzius C, Dosimetry E, Paediatrics C (2008) The new EANM paediatric dosage card: additional notes with respect to F-18. Eur J Nucl Med Mol Imaging 35(9):1666-1668
34. Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F, Dosimetry E, Paediatrics C (2007) The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 34(5):796-798
35. Kaste SC (2011) Imaging pediatric bone sarcomas. Radiol Clin North Am 49(4):749-765, vi-vii
36. Krohmer S, Sorge I, Krausse A, Kluge R, Bierbach U, Marwede D, Kahn T, Hirsch W (2010) Whole-body MRI for primary evaluation of malignant disease in children. Eur J Radiol 74(1):256-261
37. Biederer J, Hintze C, Fabel M (2008) MRI of pulmonary nodules: technique and diagnostic value. Cancer Imaging 8:125-130
38. Kwee TC, Takahara T, Vermoolen MA, Bierings MB, Mali WP, Nievelstein RA (2010) Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatr Radiol 40(10):1592-1602, quiz 1720-1591
39. Lin C, Itti E, Luciani A, Haioun C, Meignan M, Rahmouni A (2010) Whole-body diffusion-weighted imaging in lymphoma. Cancer imaging 10 Spec no A:S172-S178
40. Willowson KP, Bailey EA, Bailey DL (2012) A retrospective evaluation of radiation dose associated with low dose FDG protocols in whole-body PET/CT. Australas Phys Eng Sci Med 35(1):49-53
41. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L (2010) Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 51(8):1198-1205
42. Schwenzer NF, Schmidt H, Claussen CD (2012) Whole-body MR/PET: applications in abdominal imaging. Abdom Imaging 37(1):20-28
43. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ, Schwaiger M (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53(6):845-855
44. Antoch G, Bockisch A (2009) Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 36(Suppl 1):S113-S120
45. Chang Q, Wu N, Ouyang H, Huang Y (2012) Diffusion-weighted magnetic resonance imaging of lung cancer at 3.0 T: a preliminary study on monitoring diffusion changes during chemoradiation therapy. Clin Imaging 36(2):98-103
46. Sharma U, Baek HM, Su MY, Jagannathan NR (2011) In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients. NMR Biomed 24(6):700-711
47. Denholt CL, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen M, Hansen PR, Gillings N, Kjaer A (2011) Evaluation of 4-[18F]fluorobenzoyl-FALGEA- NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nucl Med Biol 38(4):509-515
48. Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Hojgaard L, Kjaer A (2012) Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 53(8):1207-1215
49. Jensen MM, Erichsen KD, Bjorkling F, Madsen J, Jensen PB, Hojgaard L, Sehested M, Kjaer A (2010) Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One 5(9):e12965
50. Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med 53(2):207-214
51. Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjaer A, Engelholm SA (2012) Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol 102(3):424-428
52. Oxboel J, Schoedt-Eskesen C, El-Ali H, Madsen J, Kjaer A (2012) 64Cu-NODAGA-c(RGDyK) is a promising new angiogenesis PET tracer: correlation between tumor uptake and integrin-aVß3 expression in human neuroendocrine tumor xenografts. Int J Mol Imaging 2012:379807
53. Persson M, Madsen J, Ostergaard S, Jensen MM, Jorgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A (2012) Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med 53(1):138-145
54. Persson M, Madsen J, Ostergaard S, Ploug M, Kjaer A (2012) 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 39(4):560-569
55. Sattler B, Jochimsen T, Barthel H, Sommerfeld K, Stumpp P, Hoffmann KT, Gutberlet M, Villringer A, Kahn T, Sabri O (2012) Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting. Magn Reson Mater Phy. doi: 10.1007/s10334-012-0347-2
56. Keller SH, Holm S, Hansen AE, Sattler B, Andersen F, Klausen TL, Hojgaard L, Kjaer A, Beyer T (2012) Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI. Magn Reson Mater Phy. doi: 10.1007/s10334-012-0345-4
57. Wagenknecht G, Kaiser HJ, Mottagny FM, Herzog H (2012) MRI for attenuation correction in PET: methods and challenges. Magn Reson Mater Phy. doi: 10.1007/s10334-012-0353-4